|
Invited Speakers:
|
|
| | | DISTINGUISHED SPEAKERS AND PANELISTS | | | Anne Altmeyer, Ph.D.
Executive Director, Business Development & Licensing, Oncology
Novartis
Elizabeth L. Bachert, Ph.D.
Senior Director, Worldwide Business Development
Pfizer
Michael Boretti, Ph.D.
Associate Director, Business Development
AVEO Pharmaceuticals
Matthew Call
Director, Business Development
Endocyte
Iain Dukes
Vice President, External Research & Development
Amgen
Mike Fuller
Partner
Knobbe Martens Olson & Bear
Kathleen Glaub
President, Business Development
Plexxikon
Jens Hennecke
Senior Vice President, Business Development
Micromet, Inc.
Natasha Hernday
Vice President, Business Development
Seattle Genetics
John Herrmann , Ph.D.
Senior Director, Global External Research & Development, Oncology
Eli Lilly
David Jackson, Ph.D.
Senior Director, Pharma Business Development
QIAGEN
Michael Johnson
Director, Business Development
Eli Lilly
Kevin Koch
President and Chief Scientific Officer
Array BioPharma
Sunil Patel
Senior Vice President, Corporate Development
OncoMed Pharmaceuticals
Denis Patrick, Ph.D.
Senior Director & Head, ERDI, ORU
Pfizer
Linda Pullan, Ph.D.
Business Development Consultant
(Former: VP Business Development at Kosan & Director, Licensing at Amgen)
Pullan Consulting
Jason Rhodes
Executive Vice President & Chief Business Officer
Epizyme
Josh Schafer
Global Head, Oncology Product & Portfolio Strategy
Astellas Pharma
Ginette Serrero
Chief Executive Officer
A&G Pharmaceutical
Michael M. Shih
Senior Director, Business Development
Eisai
Charles P. Theuer, M.D., Ph.D.
President and Chief Executive Officer
Tracon Pharma
Ernest Wong
Vice President, Business Development
YM Biosciences
|
|
|
|